Search Results - "Khurana, Monica" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

by Leleu, Xavier, Beksac, Meral, Chou, Takaaki, Dimopoulos, Meletios, Yoon, Sung-Soo, Prince, H. Miles, Pour, Ludek, Shelekhova, Tatiana, Chari, Ajai, Khurana, Monica, Zhang, Jianqi, Obreja, Mihaela, Qi, Ming, Oriol, Albert, Siegel, David
Published in Leukemia & lymphoma (28.01.2021)

Get full text

Journal Article

$Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial$

Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial

by Suzuki, Kenshi, Min, Chang-Ki, Kim, Kihyun, Lee, Je-Jung, Shibayama, Hirohiko, Ko, Po-Shen, Huang, Shang-Yi, Li, Sin-Syue, Ding, Bifeng, Khurana, Monica, Iida, Shinsuke
Published in International journal of hematology (01.12.2021)

Get full text

Journal Article

Trial in progress: A phase 2 study of sotorasib as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) whose tumors harbor a KRAS p.G12C mutation (CodeBreaK 201)

Trial in progress: A phase 2 study of sotorasib as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) whose tumors harbor a KRAS p.G12C mutation (CodeBreaK 201)

by Arbour, Kathryn Cecilia, Khurana, Monica, Dai, Tian, Skoulidis, Ferdinandos
Published in Journal of clinical oncology (01.06.2022)

Get full text

Journal Article

Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies

Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies

by LeBlanc, Thomas W., Baile, Walter F., Eggly, Susan, Bylund, Carma L., Kurtin, Sandra, Khurana, Monica, Najdi, Rani, Blaedel, Julie, Wolf, Jeffrey L., Fonseca, Rafael
Published in Patient education and counseling (01.09.2019)

Get full text

Journal Article

$A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly$

A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly

by Leleu, Xavier, Chari, Ajai, Richard, Shambavi, Khurana, Monica, Yusuf, Akeem, Usmani, Saad Z
Published in Expert review of hematology (02.12.2021)

Get more information

Journal Article

Fever at Diagnosis of Pediatric Acute Lymphoblastic Leukemia: Are Antibiotics Really Necessary?

Fever at Diagnosis of Pediatric Acute Lymphoblastic Leukemia: Are Antibiotics Really Necessary?

by Khurana, Monica, Lee, Brian, Feusner, James H
Published in Journal of pediatric hematology/oncology (01.10.2015)

Get more information

Journal Article

$Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m 2 and once-weekly at 70 mg/m 2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001$

Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m 2 and once-weekly at 70 mg/m 2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001

by Leleu, Xavier, Beksac, Meral, Chou, Takaaki, Dimopoulos, Meletios A., Yoon, Sung-Soo, Prince, H. Miles, Pour, Ludek, Shelekhova, Tatiana, Chari, Ajai, Khurana, Monica, Obreja, Mihaela, Qi, Ming, Oriol, Albert, Siegel, David Samuel DiCapua
Published in Journal of clinical oncology (20.05.2020)

Get full text

Journal Article

Drug-Induced Hemolytic Anemia: A Fatal Complication Further Under-Recognized in Sickle Cell Disease

Drug-Induced Hemolytic Anemia: A Fatal Complication Further Under-Recognized in Sickle Cell Disease

by Khurana, Monica, Raj, Shekhar S.
Published in Open journal of blood diseases (2017)

Get full text

Journal Article

Fever at diagnosis of pediatric acute lymphoblastic leukemia (ALL): Are antibiotics really necessary?

Fever at diagnosis of pediatric acute lymphoblastic leukemia (ALL): Are antibiotics really necessary?

by Khurana, Monica, Feusner, James Henry, Lee, Brian
Published in Journal of clinical oncology (20.05.2012)

Get full text

Journal Article

$Survey of patients and physicians on shared decisionmaking in treatment selection in relapsed/refractory multiple myeloma$

Survey of patients and physicians on shared decisionmaking in treatment selection in relapsed/refractory multiple myeloma

by Bylund, Carma L, Eggly, Susan, Leblanc, Thomas W, Ku, Gandee, Marianne, Medhekar, Rohan, Fu, Alan, Khurana, Monica, Delaney, Kara, Divita, Alecia, Mcnamara, Michelle, Baile, Walter F
Published in Translational behavioral medicine (01.04.2023)

Get full text

Journal Article

Lung clearance index in children with sickle cell disease

Lung clearance index in children with sickle cell disease

by Machogu, Evans M., Khurana, Monica, Kaericher, Jennifer, Clem, Charles C., Slaven, James E., Hatch, Joseph E., Davis, Stephanie D., Peterson‐Carmichael, Stacey
Published in Pediatric pulmonology (01.05.2021)

Get full text

Journal Article

$Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma$

Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma

by Bylund, Carma L, Eggly, Susan, LeBlanc, Thomas W, Kurtin, Sandra, Gandee, Marianne, Medhekar, Rohan, Fu, Alan, Khurana, Monica, Delaney, Kara, Divita, Alecia, McNamara, Michelle, Baile, Walter F
Published in Translational behavioral medicine (15.04.2023)

Get full text

Journal Article

P-206: SELECT Trial in Progress: an open-label, phase 2 study of Carfilzomib, Pomalidomide, and Dexamethasone in patients with first or second relapse of Multiple Myeloma

P-206: SELECT Trial in Progress: an open-label, phase 2 study of Carfilzomib, Pomalidomide, and Dexamethasone in patients with first or second relapse of Multiple Myeloma

by Moreau, Philippe, Delimpasi, Sosana, Katodritou, Eirini, Belotti, Angelo, Melear, Jason, Frolund, Ulf, Rosiñol, Laura, Besemer, Britta, Yusuf, Akeem, Khurana, Monica, Yang, Zhao, Dimopoulos, Meletios-Athanasios
Published in Clinical lymphoma, myeloma and leukemia (01.10.2021)

Get full text

Journal Article

$P-204: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease$

P-204: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease

by Mateos, María-Victoria, Usmani, Saad Z., Quach, Hang, Dimopoulos, Meletios-Athanasios, Fonseca, Rafael, McFadden, Ian, Yusuf, Akeem, Khurana, Monica, Obreja, Mihaela, Spencer, Andrew
Published in Clinical lymphoma, myeloma and leukemia (01.10.2021)

Get full text

Journal Article

Recurrent Metastatic High-Grade Osteosarcoma: Disease Stabilization and Successful Pregnancy Outcome following Aggressive Multimodality Treatment

Recurrent Metastatic High-Grade Osteosarcoma: Disease Stabilization and Successful Pregnancy Outcome following Aggressive Multimodality Treatment

by Khurana, Monica, Gruner, Barbara, Sathi, Bindu Kanathezhath
Published in Indian journal of medical and paediatric oncology (01.10.2018)

Get full text

Journal Article

$An Open-Label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers$

An Open-Label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

by Fonseca, Rafael, Alsina, Melissa, Berdeja, Jesus, Heitner, Stephen B., Morris, Christopher, Khurana, Monica, Niesvizky, Ruben
Published in Clinical lymphoma, myeloma and leukemia (01.09.2018)

Get full text

Journal Article

Identifying Ultra-High Risk Smoldering Multiple Myeloma

Identifying Ultra-High Risk Smoldering Multiple Myeloma

by Akhlaghi, Theresia, Rustad, Even H, Yellapantula, Venkata D, Korde, Neha, Mailankody, Sham, Lendvai, Nikoletta, Lesokhin, Alexander M., Hassoun, Hani, Giralt, Sergio, Landau, Heather J., Smith, Eric L., Shah, Gunjan L., Scordo, Michael, Chung, David J., Mezzi, Khalid, Khurana, Monica, Braunlin, Megan, Werther, Winifred, Landgren, Ola, Hultcrantz, Malin
Published in Blood (29.11.2018)

Get full text

Journal Article

$A Patient-Physician Tool to Improve CoMMunication in Relapsed Refractory Multiple Myeloma (RRMM)$

A Patient-Physician Tool to Improve CoMMunication in Relapsed Refractory Multiple Myeloma (RRMM)

by Leblanc, Thomas, Eggly, Susan, Bylund, Carmen, Khurana, Monica, Najdi, Rani, Blaedel, Julie, Medhekar, Rohan, Fu, Alan, Rosenberg, Aaron Seth, Copur, Mehmet, Baile, Walter
Published in Clinical lymphoma, myeloma and leukemia (01.10.2019)

Get full text

Journal Article

$MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies$

MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

by Leleu, Xavier, Beksac, Meral, Chou, Takaaki, Dimopoulos, Meletios, Yoon, Sung-Soo, Prince, Henry Miles, Pour, Ludek, Shelekhova, Tatiana, Chari, Ajai, Khurana, Monica, Obreja, Mihaela, Qi, Ming, Oriol, Albert, Siegel, David
Published in Clinical lymphoma, myeloma and leukemia (01.09.2020)

Get full text

Journal Article

Risk for CMV reactivation in children undergoing allogeneic hematopoietic stem cell transplantation

Risk for CMV reactivation in children undergoing allogeneic hematopoietic stem cell transplantation

by Qayed, Muna, Khurana, Monica, Hilinski, Joseph, Gillespie, Scott, McCracken, Courtney, Applegate, Kristy, Chiang, Kuang-Yueh, Horan, John
Published in Pediatric blood & cancer (01.02.2015)

Get full text

Journal Article